SNV1521 for Advanced Solid Tumors
This study is testing a new oral medication called SNV1521 for people with advanced solid tumors. Researchers want to see if SNV1521 is safe and well-tolerated, and if it can help treat these cancers. They are also exploring different doses and if SNV1521 can be combined with other treatments like DB-1310, Abiraterone, or Darolutamide. You might be able to join if you have an advanced or metastatic (spread to other parts of the body) solid tumor, a good performance status (ECOG 0 or 1), and a life expectancy of over 3 months. The study aims to enroll 400 participants.
- Study design
- This is an interventional study with a planned enrollment of 400 participants. It is testing different doses of SNV1521, alone or in combination with other drugs.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be monitored from the first dose through the last dose, up to 13 months. Tolerability will be assessed during the first 28-day cycle.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SNV1521 in Participants With Advanced Solid Tumors
At a glance
Conditions
NCT06220864
Where you'd take part
This study runs at 25 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
AZ Groeninge
Kortrijk, Belgiumstudy coordinator listed
Recruiting
AZ Maria Middelares
Ghent, Belgiumstudy coordinator listed
Recruiting
The Institut Jules Bordet
Brussels, Belgiumstudy coordinator listed
Recruiting
University Center for Clinical Research Antwerp (UNICCRA)
Edegem, Belgiumstudy coordinator listed
Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canadano site contact published
Recruiting
Gustave Roussy
Villejuif, Franceno site contact published
Recruiting
Institut Bergonie
Bordeaux, Franceno site contact published
Recruiting
Istituto Clinico Humanitas
Milan, Italyno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Safety of SNV1521From first dose through last dose (up to 13 months)
Treatment emergent adverse events (TEAEs)
- Tolerability of SNV1521DLTs: From first dose through completion of first cycle (28 days)
Incidence and frequency of dose-limiting toxicities (DLTs) (Dose-escalation arm only)